Not sure... I have always thought Painchek is trying to balance between a patient centric healthcare company vs a for profit hype micro-cap company. It has certainly leaned towards the former at the detriment of abysmal TSR for the past 2.5 years.
That said though.. I don't like the 4C update on assessments # vs the presentation.. the 4C commentary stipulated a much higher assessments done in the quarter vs what is shown on the investor presentation.. it's either misleading on intention or unprofessional in its proof reading.
PCK Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
